Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.

IF 1.5 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-05-23 DOI:10.1080/14737167.2025.2505726

E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias

{"title":"Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.","authors":"E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias","doi":"10.1080/14737167.2025.2505726","DOIUrl":null,"url":null,"abstract":"Background: Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.Methods: A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.Results: HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.Conclusions: Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1063-1072"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2025.2505726","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.

Methods: A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.

Results: HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.

Conclusions: Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.

查看原文本刊更多论文

希腊转移性去势抵抗性前列腺癌患者的医疗资源利用及相关费用

背景：前列腺癌是男性癌症死亡的主要原因。转移性去势抵抗性前列腺癌（mCRPC）的治疗发生了巨大变化，因为引入了新的激素制剂（NHAs）；然而，希腊缺乏包括医疗资源利用率（HCRU）和成本在内的真实数据。方法：一组HCRU患者数据来自PROSPECT回顾性图表回顾研究，该研究纳入了一线（1l）全身治疗化疗或nha的mCRPC患者；估计了mCRPC治疗期间的HCRU和费用。结果：在纳入的119例患者中，HCRU基本上保持稳定。总体而言，HCRU成本中位数为每位患者每月2,363.8欧元（PPPM）；1升为2475.0欧元，二线（2升）为1698.9欧元，三线（3升）为2499.0欧元。费用主要由全身治疗组成（约90%）。总体HCRU 2 L成本为688,795.1欧元，在研究的三条线路中占HCRU总成本的比例最低（3,820,561.1欧元）。2 L的成本比1 L或3 L的患者接受化疗的比例更低，化疗比nha更便宜。结论：系统治疗类型对成本有影响；2 L的治疗费用较低，因为更多的患者接受化疗而不是nha治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.